Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

ADC THERAPEUTICS SA

(ADCT)
  Report
Delayed Nyse  -  04:00 2022-11-29 pm EST
3.380 USD   -0.59%
11/28Biocytogen Enters into Antibody Agreement with ADC Therapeutics
BU
11/28ADC Therapeutics, Biocytogen Pharmaceuticals Sign Antibody License Deal for Tumor Targets
MT
11/14Sobi to present new data at the ASH 2022 Annual Meeting
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
Days
:
Hours
:
Minutes
:
Seconds
Valuation
Fiscal Period: December 2020 2021 2022 2023 2024
Capitalization1 2 4851 550270--
Enterprise Value (EV)1 2 0871 092-38,7123218
P/E ratio -8,49x-6,73x-1,66x-1,50x-1,47x
Yield -----
Capitalization / Revenue -45,7x1,38x1,56x1,47x
EV / Revenue -32,2x-0,20x0,71x1,19x
EV / EBITDA -11,6x-5,50x0,32x-0,63x-1,25x
Price to Book 7,32x9,34x3,02x-3,89x-1,05x
Nbr of stocks (in thousands) 77 61976 75479 934--
Reference price (USD) 32,020,23,383,383,38
Announcement Date 03/18/202103/03/2022---
1 USD in Million
Estimates
Income Statement Evolution (Annual data)
Fiscal Period: December 2019 2020 2021 2022 2023 2024
Net sales1 2,34-33,9196174184
EBITDA1 --179-199-119-196-175
Operating profit (EBIT)1 --219-262-137-182-207
Operating Margin ---772%-70,3%-105%-113%
Pre-Tax Profit (EBT)1 --246-252-161-194-223
Net income1 --246-230-159-203-231
Net margin ---678%-81,4%-117%-126%
EPS2 -2,36-3,77-3,00-2,03-2,26-2,31
Dividend per Share2 ------
Announcement Date 04/24/202003/18/202103/03/2022---
1 USD in Million
2 USD
Estimates
Income Statement Evolution (Quarterly data)
Fiscal Period: December 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2
Net sales1 46,517,376,327,814927,1
EBITDA ------
Operating profit (EBIT)1 -40,4-69,4-3,11-56,856,6-68,8
Operating Margin -86,8%-401%-4,08%-205%38,0%-254%
Pre-Tax Profit (EBT)1 -17,8-65,3-51,3-25,847,3-77,4
Net income1 -16,7-64,4-50,6-25,317,6-82,8
Net margin -35,8%-372%-66,3%-91,2%11,8%-305%
EPS2 -0,22-0,84-0,65-0,31-0,29-0,83
Dividend per Share ------
Announcement Date 05/09/202208/09/202211/08/2022---
1 USD in Million
2 USD
Previous periodNext period
Estimates
Balance Sheet Analysis
Fiscal Period: December 2019 2020 2021 2022 2023 2024
Net Debt1 ------
Net Cash position1 -39745930914752,1
Leverage (Debt / EBITDA) -2,21x2,31x2,59x0,75x0,30x
Free Cash Flow1 ---237-30,0-144-94,4
ROE (Net Profit / Equities) --110%-91,7%-78,8%-448%-
Shareholders' equity1 -22325120245,2-
ROA (Net Profit / Asset) ----14,2%-49,8%-67,8%
Assets1 ---1 120407341
Book Value Per Share2 -4,372,161,12-0,87-3,21
Cash Flow per Share --2,58----
Capex1 -0,803,433,005,4011,2
Capex / Sales --10,1%1,53%3,11%6,09%
Announcement Date 04/24/202003/18/202103/03/2022---
1 USD in Million
2 USD
Estimates
Key data
Capitalization (USD) 270 178 079
Net sales (USD) 33 917 000
Number of employees 312
Sales / Employee (USD) 108 708
Free-Float 46,9%
Free-Float capitalization (USD) 126 703 188
Avg. Exchange 20 sessions (USD) 2 106 461
Average Daily Capital Traded 0,78%
EPS & Dividend